Morgan Stanley analyst Mark Purcell raised the firm’s price target on AstraZeneca to 12,900 GBp from 12,700 GBp and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Microsoft upgraded, Nike downgraded: Wall Street’s top analyst calls
- AstraZeneca upgraded to Buy from Hold at Jefferies
- AstraZeneca says Dato-DXd showed significant improvement for primary endpoint
- AstraZeneca says Dato-DXd improved PFS in breast cancer trial